Status:
UNKNOWN
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome
Lead Sponsor:
Faculty Hospital Kralovske Vinohrady
Conditions:
Obstructive Sleep Apnea
Obesity
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Obstructive sleep apnea syndrome (OSA) represents highly prevalent (typically overlooked, undiagnosed and untreated) disorder significantly increasing cardiovascular, cancer and overall mortality as w...
Detailed Description
Obstructive sleep apnea (OSA) is a common condition affecting 5-15% of the general population characterized by a repetitive collapse of the upper airway during sleep. The ensuing apneas and hypopneas ...
Eligibility Criteria
Inclusion
- mild (AHI \< 10) or severe (AHI \> 30) OSA diagnosed by home sleep study
- BMI 30-40 kg/m2
- age 18 - 65 years
- absence of diabetes mellitus (fasting glucose level \< 7 mmol/l, HBA1c \< 48 mmol/l and oGTT \< 11.1 mmol/L 2 hours after 75g oral glucose load)
- no treatment with drugs affecting lipolysis (betablockers, alpha adrenergic blockers, glucocorticoids).
Exclusion
- cardiac, renal or respiratory; chronic inflammatory or cancer disease
- body weight change more than 5 kg in last 3 months
- inability to participate in the life-style program
- inability to give an informed consent
- participation in another research project
- pregnancy or planned pregnancy during the study period
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05245240
Start Date
January 1 2022
End Date
December 1 2024
Last Update
February 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Královské Vinohrady
Prague, Czechia, 100 34